论文部分内容阅读
非酒精性脂肪性肝在发达国家和发展中国家中是一种常见的肝脏疾病。引起非酒精性脂肪性肝病的最常见原因有肥胖、糖尿病和高胆固醇。尽管非酒精性脂肪性肝病的发病率日益升高,事实上至今尚未发现可以用于治疗的药物。山楂酸是一种五环三萜化合物,已报道具有多种药理特性,包括抗炎、抗氧化以及免疫调节作用。我们的前期研究表明,山楂酸能够抑制高脂饲料诱导大鼠非酒精性脂肪性肝病的生成。本研究中,我们将探讨山楂酸体外对肝细胞(LO2)脂质累积的抑制作用。结果表明,山楂酸可抑制游离脂肪酸(FFA)诱导的LO2细胞脂质累积,进一步研究表明,山楂酸可抑制LO2细胞的SCAP mRNA水平和蛋白水平的表达。
Non-alcoholic fatty liver is a common liver disease in both developed and developing countries. The most common causes of nonalcoholic fatty liver disease are obesity, diabetes and high cholesterol. Despite the increasing incidence of nonalcoholic fatty liver disease, virtually no drug that has been found to be available for treatment has so far been discovered. Maslinic acid is a pentacyclic triterpenoid compound that has been reported to have a variety of pharmacological properties including anti-inflammatory, anti-oxidant and immunomodulatory effects. Our previous studies showed that maslinic acid can inhibit the production of nonalcoholic fatty liver disease induced by high fat diet in rats. In this study, we will investigate the inhibitory effect of maslinic acid on lipid accumulation in hepatocytes (LO2) in vitro. The results showed that maslinic acid could inhibit the lipid accumulation of LO2 cells induced by free fatty acid (FFA). Further studies showed that maslinic acid could inhibit the expression of SCAP mRNA and protein in LO2 cells.